Vera Therapeutics, Inc. (NASDAQ:VERA) Director Beth C. Seidenberg Sells 1,177 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Beth C. Seidenberg sold 1,177 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the completion of the transaction, the director now directly owns 160,376 shares in the company, valued at approximately $6,737,395.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vera Therapeutics Stock Performance

NASDAQ VERA opened at $42.78 on Friday. Vera Therapeutics, Inc. has a fifty-two week low of $9.24 and a fifty-two week high of $50.78. The business’s 50 day moving average price is $37.35 and its 200-day moving average price is $39.11. The company has a market cap of $2.34 billion, a P/E ratio of -20.87 and a beta of 0.99. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Sell-side analysts predict that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of VERA. Public Employees Retirement Association of Colorado purchased a new stake in shares of Vera Therapeutics during the second quarter worth about $135,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Vera Therapeutics during the 2nd quarter valued at approximately $163,000. Ameritas Investment Partners Inc. raised its holdings in shares of Vera Therapeutics by 20.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after buying an additional 688 shares during the last quarter. Cetera Advisors LLC purchased a new stake in shares of Vera Therapeutics during the first quarter valued at $235,000. Finally, Quarry LP purchased a new position in shares of Vera Therapeutics in the second quarter worth about $235,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on VERA. JPMorgan Chase & Co. upped their price target on Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research note on Monday, September 16th. Finally, Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $51.75.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.